T1D Fund

T1D Fund investment thesis

Supporting The Next Generation Of T1D Treatments The T1D Fund is uniquely positioned to transform the T1D therapeutic landscape through impact investment We invest in opportunities that reduce developmental risk, accelerate progress, and generate returns—all of which are reinvested into the Fund to fuel future investments in breakthrough T1D treatments (neither management nor donors receive distributions). Given the Fund is an affiliate of Breakthrough T1D, a 501(c)(3) organization, all donor contributions raised for the Fund are recorded as charitable donations where donors receive tax benefits at the time of contribution. Our impact investing approach and reputation as a leader in the field enable us to attract top-tier investors and build strong syndicates to fund transformative T1D inn

T1D Fund team (6)

Partners and principals at T1D Fund:

• John Ballew — sweet spot $1.5M
• Rachel Cotton — sweet spot $1.5M
• Katie Ellias — sweet spot $1.5M
• Yury Kukushkin — sweet spot $1.5M
• Amy Montalto — sweet spot $1.5M
• Steven St. Peter — sweet spot $1.5M

T1D Fund portfolio companies

Companies listed on T1D Fund's public materials include: Donor Login, Breakthrough T1D, About, Investment Strategy, Portfolio, News, Get in Touch, Show All, Active Portfolio, Exited Portfolio, AltruBio, Aspect Biosystems, Aurimi Therapeutics, Bigfoot Biomedical, Biolinq, Capillary Biomedical, Century Therapeutics, COUR Pharmaceuticals, Diasome Pharmaceuticals, DiogenX, Egle Therapeutics, Eledon Pharmaceuticals, GentiBio, Immunocore, Inversago Pharma, Jaguar Gene Therapy, Kriya Therapeutics, Mozart Therapeutics, Orizuru Therapeutics, Pandion Therapeutics, Protomer Technologies, Provention Bio, Sab Biotherapeutics, Sana Biotechnology, Semma Therapeutics, Sonoma Biotherapeutics, vTv Therapeutics, ZagBio, Zucara Therapeutics, About The T1D Fund, info@t1dfund.org.

Is T1D Fund a fit for your round?

Upload your pitch deck and see whether anyone at T1D Fund appears in your top matches.